- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03582930
Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)
November 3, 2023 updated by: ONY
Surfactant replacement therapy can be life-saving for newborn infants born with symptomatic lung surfactant deficiency causing Respiratory Distress Syndrome (RDS).
Currently, such therapy requires instillation of a liquid suspension into the trachea through an endotracheal tube.
Endotracheal intubations have undesirable adverse effects on fragile premature infants.
Instilling surfactant as a liquid suspension into the lung is associated with adverse events due to interruption of breathing in patients who already have respiratory insufficiency.
This treatment protocol is expanded access that offers the opportunity for patients to receive aerosolized Infasurf prior to FDA acting on ONY Biotech's application for approval for commercial marketing of aerosolized Infasurf.
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Detailed Description
This Treatment Protocol will offer patients access to aerosolized Infasurf therapy at the time RDS is diagnosed if a patient is <12 hours of age and has not previously received liquid surfactant, or is <24 hours of age, and received liquid surfactant in the first hour after birth, was extubated and RDS is worsening.
Parents must give informed consent.
Up to 2 repeat doses of aerosolized Infasurf can be administered.
Aerosolized Infasurf must be administered as described in the protocol.
Adverse events at administration (if any) and all serious adverse events related or possibly related the aerosolized Infasurf therapy will be extracted from the medical record and reported to the sponsor, ONY Biotech.
A copy of the discharge summary of patients will be collected by the sponsor using HIPAA compliant methodology for generation of a data set that will characterize adverse events and other efficacy and safety data.
Study Type
Expanded Access
Expanded Access Type
- Treatment IND/Protocol
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Corey Commaroto, RRT
- Phone Number: 124 7164283124
- Email: ccommaroto@onybiotech.com
Study Contact Backup
- Name: Dan Swartz, PhD
- Email: Info@onybiotech.com
Study Locations
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
New York
-
Buffalo, New York, United States, 14214
- Sisters of Charity Hospital
-
-
North Carolina
-
Greenville, North Carolina, United States, 27835
- Pitt County Memorial Hospital
-
-
Tennessee
-
Jackson, Tennessee, United States, 38301
- Jackson-Madison County General Hospital
-
-
Utah
-
Provo, Utah, United States, 84604
- Utah Valley Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 9 months (Child)
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
Two cohorts with different entry criteria are included. In cohort 1 are patients with a diagnosis of early RDS who are not intubated and have not received a liquid surfactant instillation. In cohort 2 are patients who received liquid surfactant in the first hour of life, have been extubated and whose RDS is worsening.
Cohort 1 Inclusion Criteria
- NICU patient, <12 hours of age.
- Clinical diagnosis of RDS, with or without chest X-ray data.
- Inspired oxygen ≤40% to maintain adequate oxygen saturation.
- Not intubated
- Requiring: (a) nasal continuous positive airway pressure (nCPAP), or (b) high flow nasal cannula (≥2L/kg/min) (HFNC), or (c) non-invasive ventilation.
Cohort 2 Inclusion Criteria
- NICU patient, <24 hours of age who received liquid surfactant at ≤ 1 hour of age and was extubated.
- Clinical diagnosis of RDS, with or without chest X-ray data.
- Inspired oxygen ≤40% to maintain adequate oxygen saturation.
- Not intubated
- Requiring: (a) nasal continuous positive airway pressure (nCPAP), or (b) high flow nasal cannula (≥2L/kg/min) (HFNC), or (c) non-invasive ventilation.
Exclusion Criteria:
- 1) Requires >40% inspired oxygen to maintain acceptable oxygenation 2) Requires endotracheal intubation. 3) A co-existing medical condition that makes aerosol administration contraindicated in the judgment of the attending physician.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Jim Cummings, MD, Albany Medical College
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
June 27, 2018
First Submitted That Met QC Criteria
June 27, 2018
First Posted (Actual)
July 11, 2018
Study Record Updates
Last Update Posted (Actual)
November 7, 2023
Last Update Submitted That Met QC Criteria
November 3, 2023
Last Verified
October 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Aero-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Respiratory Distress
-
Murdoch Childrens Research InstituteUniversity College Hospital, Ibadan; University of Ibadan; University of Tasmania and other collaboratorsCompletedPrematurity | Oxygen Toxicity | Neonatal Respiratory Distress Related Conditions | Neonatal Respiratory FailureNigeria
-
Assiut UniversityRecruitingNeonatal Respiratory DistressEgypt
-
Groupe Hospitalier Paris Saint JosephCompletedEarly Neonatal Respiratory Distress: Changes in Level IIb Hospital Over a Period of One Year (DROPE)Neonatal Respiratory Distress SyndromeFrance
-
University of California, DavisWithdrawnNeonatal Respiratory Distress Related ConditionsUnited States
-
Loma Linda UniversityNot yet recruiting
-
ONYAvaniaNot yet recruitingIntubation Complication | Death; Neonatal | Respiratory Distress Syndrome (Neonatal)United States
-
Imperial College Healthcare NHS TrustTerminatedBreast Feeding | Continuous Positive Airway Pressure | Infant, Premature | Neonatal Respiratory Distress Syndrome | Intensive Care, NeonatalUnited Kingdom
-
University of AlbertaNot yet recruitingNeonatal Respiratory DistressCanada
-
Englewood Hospital and Medical CenterTerminatedNeonatal Respiratory DistressUnited States
-
Assiut UniversityUnknown
Clinical Trials on Infasurf Aero
-
ONYAvaniaNot yet recruitingIntubation Complication | Death; Neonatal | Respiratory Distress Syndrome (Neonatal)United States
-
Jena University HospitalUniversity of Jena; National Research Centre of Complementary and Alternative... and other collaboratorsCompleted
-
Hochschule OsnabruckLMU KlinikumRecruitingOsteoporosis | Bone Loss | OsteopeniaGermany
-
Roberta BallardMallinckrodt; ONYCompletedBronchopulmonary Dysplasia | Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction)United States
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; Women & Children's Hospital of BuffaloCompletedPilot Trial of Surfactant Therapy For Preterm Neonates 5-21 Days Old With Respiratory DecompensationRespiratory Distress Syndrome
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; Children's Mercy Hospital Kansas City; St. Louis... and other collaboratorsCompletedRespiratory Distress Syndrome | Bronchopulmonary Dysplasia
-
ONYTerminated
-
University of Missouri-ColumbiaCompletedRespiratory Distress SyndromeUnited States
-
University of PittsburghCystic Fibrosis FoundationCompleted
-
Instituto de Cardiologia do Rio Grande do SulCompletedCoronary Artery Disease | Cardiac Rehabilitation | Coronary Artery Bypass GraftingBrazil